Alcon’s Tryptyr approved by FDA for signs and symptoms of Dry Eye Disease

Alcon (ALC) announced the FDA has approved Tryptyr – acoltremon ophthalmic solution – 0.003%, formerly known as AR-15512, for the treatment of signs and symptoms of Dry Eye Disease. Tryptyr is a first-in-class TRPM8 receptor agonist that stimulates corneal sensory nerves to rapidly increase natural tear production. This approval is supported by two Phase 3 clinical trials evaluating more than 930 patients in which up to four times more Tryptyr patients experienced at least a 10mm increase in natural tear production at Day 14. Tryptyr demonstrated statistically significant natural tear production as early as Day 1. Alcon expects to launch Tryptyr in the U.S. in Q3 2025 and anticipates bringing Tryptyr to other markets in the future.